Pipeline


Porton Biopharma, is working together with Public Health England and US company NanoBio Inc. to develop a next generation anthrax vaccine at PBL’s facilities in Porton, Wiltshire, UK. This programme is currently funded by the US Government, through its National Institute of Allergy and Infectious Diseases (NIAID) and could be worth up to £14m ($24m) over the next few years.

If successful the next generation vaccine will combine the PBL’s expertise with anthrax vaccine antigens and US Company NanoBio Inc’s stabilisation technology enabling immunity to be achieved by fewer doses than current vaccines and by intra-nasal spray device instead of an injection.